Evocutis plc, the UK dermatology company, has announced its unaudited interim results for the six months ended 31 January, 2013.
The company reported a revenue of £226,000, up from £344,000 in H1 2012, while the cash balance totalled £1,030,000 at 31 January 2013. Adjusted operating loss totalled £476,000, while basic loss per share equalled 0.28p per share.
Operation highlights in the reporting period include the launch of LabSkin for direct sale in September 2012, and laboratory studies of LabSkin, which demonstrated its value as a living model system for studies of transdermal drug delivery, complementing the use of excised, non-living human or pig skin systems.